AIOP LAM 2002 chemotherapy schedule
| Phase . | Week . | Administration route . | Doses . | Days . |
|---|---|---|---|---|
| Remission induction (ICE ×2) | ||||
| Idarubicin | 1, 4 | IV | 10 mg/m2 | 1, 2, 3 |
| Etoposide | 1, 4 | IV | 100 mg/m2 | 1, 2, 3, 4, 5 |
| Cytarabine | 1, 4 | IV (24 h) | 200 mg/m2 | 1, 2, 3, 4, 5, 6, 7 |
| IT therapy | 1, 4 | |||
| Cytarabine | 1, 4 | IT | Depending on age* | 1 |
| Methotrexate (only for CNS disease) | 1, 4 | IT | Depending on age* | 1, 4, 7, 10, 14 of first cycle |
| Methylprednisolone (only for CNS disease) | 1, 4 | IT | Depending on age* | 1, 4, 7, 10, 14 of first cycle |
| Consolidation 1 (AVE) | ||||
| Etoposide | 8 | IV | 125 mg/m2 | 2, 3, 4, 5 |
| Cytarabine | 8 | IV | 3 g/m2 bid | 1, 2, 3 |
| IT therapy | ||||
| Cytarabine | 8 | IT | Depending on age* | 6 |
| Consolidation 2 (HAM) | ||||
| Cytarabine | 11 | IV | 3 g/m2 bid | 1, 2, 3 |
| Mitoxantrone | 11 | IV | 10 mg/m2 | 3, 4 |
| IT therapy | ||||
| Cytarabine | 11 | IT | Depending on age* | 6 |
| Consolidation 3 (HD Ara-C) (only for SR) | ||||
| Cytarabine | 14 | IV | 3 g/m2 bid | 1, 2, 3 |
| IT therapy | ||||
| Cytarabine | 14 | IT | Depending on age* | 6 |
| Phase . | Week . | Administration route . | Doses . | Days . |
|---|---|---|---|---|
| Remission induction (ICE ×2) | ||||
| Idarubicin | 1, 4 | IV | 10 mg/m2 | 1, 2, 3 |
| Etoposide | 1, 4 | IV | 100 mg/m2 | 1, 2, 3, 4, 5 |
| Cytarabine | 1, 4 | IV (24 h) | 200 mg/m2 | 1, 2, 3, 4, 5, 6, 7 |
| IT therapy | 1, 4 | |||
| Cytarabine | 1, 4 | IT | Depending on age* | 1 |
| Methotrexate (only for CNS disease) | 1, 4 | IT | Depending on age* | 1, 4, 7, 10, 14 of first cycle |
| Methylprednisolone (only for CNS disease) | 1, 4 | IT | Depending on age* | 1, 4, 7, 10, 14 of first cycle |
| Consolidation 1 (AVE) | ||||
| Etoposide | 8 | IV | 125 mg/m2 | 2, 3, 4, 5 |
| Cytarabine | 8 | IV | 3 g/m2 bid | 1, 2, 3 |
| IT therapy | ||||
| Cytarabine | 8 | IT | Depending on age* | 6 |
| Consolidation 2 (HAM) | ||||
| Cytarabine | 11 | IV | 3 g/m2 bid | 1, 2, 3 |
| Mitoxantrone | 11 | IV | 10 mg/m2 | 3, 4 |
| IT therapy | ||||
| Cytarabine | 11 | IT | Depending on age* | 6 |
| Consolidation 3 (HD Ara-C) (only for SR) | ||||
| Cytarabine | 14 | IV | 3 g/m2 bid | 1, 2, 3 |
| IT therapy | ||||
| Cytarabine | 14 | IT | Depending on age* | 6 |
CNS disease was considered as presence of >5 leukemia blasts in the cerebrospinal fluid, or nerve palsy or CNS involvement, at either nuclear magnetic resonance or at computed tomography scan.
AVE, high-dose cytarabine; bid, twice daily; HAM, HD Ara-C and mitoxantrone; IT, intrathecal; IV, intravenous.
Children <1 year received 20 mg cytarabine, while those aged between 1 and 2, or 2 and 3, or >3 years were given 30, 50, and 70 mg, respectively.